Annexin Pharmaceuticals AB (OSTO:ANNX) Non Operating Income: kr0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ANNX Annexin Pharmaceuticals AB OSTO:ANNX
16 GF Score
Price kr13.45
! 1 Warning Sign
View Full Analysis

What is Annexin Pharmaceuticals AB Non Operating Income?

Annexin Pharmaceuticals AB OSTO:ANNX +2.67% 16 Non Operating Income is kr0.00 Mil as of Jun. 2026. GuruFocus rates OSTO:ANNX with a GF Score™ of 16/100. The stock has 1 warning sign investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Annexin Pharmaceuticals AB's Non Operating Income for the three months ended in Jun. 2026 was kr0.00 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was kr0.00 Mil.

Annexin Pharmaceuticals AB Non Operating Income Related Terms

Annexin Pharmaceuticals AB Non Operating Income Historical Data

* Premium members only.

The historical data trend for Annexin Pharmaceuticals AB's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annexin Pharmaceuticals AB Non Operating Income Chart

Annexin Pharmaceuticals AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Annexin Pharmaceuticals AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
OSTO:ANNX
16GF Score
Annexin Pharmaceuticals AB OSTO:ANNX
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annexin Pharmaceuticals AB Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of kr0.00 Mil mean?
Annexin Pharmaceuticals AB (OSTO:ANNX) has a Non Operating Income of kr0.00 Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Annexin Pharmaceuticals AB and its competitors.
Is Annexin Pharmaceuticals AB's Non Operating Income too high?
Annexin Pharmaceuticals AB's current Non Operating Income is kr0.00 Mil. Overall, Annexin Pharmaceuticals AB has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Annexin Pharmaceuticals AB's Non Operating Income compare to VRTX and REGN?
Annexin Pharmaceuticals AB's Non Operating Income of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Annexin Pharmaceuticals AB and its competitors. Annexin Pharmaceuticals AB's current Non Operating Income is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annexin Pharmaceuticals AB stock overvalued right now?
Annexin Pharmaceuticals AB (OSTO:ANNX) has a current Non Operating Income of kr0.00 Mil. The current Non Operating Income is kr0.00 Mil. Annexin Pharmaceuticals AB's overall GF Score™ is 16/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Annexin Pharmaceuticals AB (OSTO:ANNX), the current Non Operating Income is kr0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Annexin Pharmaceuticals AB Business Description

Other Exchanges Q910:Germany
Address Kammakargatan 48, Stockholm, SWE, 111 60
Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.
16GF Score

Get the complete analysis for OSTO:ANNX

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr13.45
Price